Search This Blog

Thursday, December 29, 2022

MediWound, Vericel: FDA OKs NexoBrid® for the Treatment of Severe Thermal Burns

 Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns

Triggers $7.5 million milestone payment from Vericel Corporation; NexoBrid is anticipated to be commercially available in the U.S. in the second quarter of 2023

https://finance.yahoo.com/news/mediwound-announces-fda-approval-nexobrid-184600392.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.